ストックスクリーナーアプリを入手
8.24
0.24%
-0.02
プレマーケット:
8.49
0.25
+3.03%
前日終値:
$8.26
開ける：
$8.26
24時間の取引高:
780.49K
Relative Volume:
0.57
時価総額：
$499.26M
収益：
$217.11M
当期純損益:
$-651.19M
株価収益率:
-0.6343
EPS:
-12.99
ネットキャッシュフロー:
$-387.26M
1週間 パフォーマンス:
-15.75%
1か月 パフォーマンス:
+5.91%
6か月 パフォーマンス:
-3.63%
1年 パフォーマンス:
-14.26%
1日の値動き範囲:
$8.17
$8.60
1週間の範囲:
$8.17
$10.08
52週間の値動き範囲:
$5.00
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
名前
Ginkgo Bioworks Holdings Inc
セクター
電話
(877) 442-5362
住所
27 DRYDOCK AVENUE, BOSTON
DNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.24 | 500.48M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-15 | ダウングレード | BTIG Research | Neutral → Sell |
| 2024-05-10 | ダウングレード | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-06-02 | ダウングレード | Goldman | Neutral → Sell |
| 2023-05-11 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | 開始されました | Berenberg | Buy |
| 2022-10-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-18 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-03-02 | 再開されました | Cowen | Outperform |
| 2022-02-23 | 開始されました | Goldman | Neutral |
| 2022-02-01 | 開始されました | BofA Securities | Neutral |
| 2022-01-28 | 開始されました | BofA Securities | Buy |
| 2022-01-07 | 開始されました | BTIG Research | Buy |
| 2021-11-29 | 開始されました | Jefferies | Buy |
| 2021-10-13 | 開始されました | Raymond James | Outperform |
| 2021-10-12 | 開始されました | William Blair | Outperform |
| 2021-09-20 | 開始されました | HSBC Securities | Buy |
すべてを表示
Ginkgo Bioworks Holdings Inc (DNA) 最新ニュース
Ginkgo Bioworks, Agricen Collaborate on Soil Amendment Fermentation - marketscreener.com
Ginkgo Bioworks and Agricen complete fermentation process optimization By Investing.com - Investing.com Canada
New partnership speeds up production of helpful soil bacteria for crops - Stock Titan
DNA (NYSE: DNA) holder plans sale of 736 Class A shares on NYSE per notice - Stock Titan
Price-Driven Insight from (DNA) for Rule-Based Strategy - news.stocktradersdaily.com
What analysts say about Ginkgo Bioworks Holdings Inc stockDividend Stability Analysis & Rapid Portfolio Gain - earlytimes.in
Ginkgo Bioworks awarded four-year, up to $47M contract from EMSL - MSN
Is Ginkgo Bioworks Holdings Inc a good long term investmentSector-Based Investing & Rapid Capital Appreciation - earlytimes.in
ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - Investing News Network
Jump Financial LLC Acquires New Stake in Ginkgo Bioworks Holdings, Inc. $DNA - MarketBeat
Treas Che Files To Sell 2,200 Of Ginkgo Bioworks Holdings Inc [DNA] - TradingView — Track All Markets
Ginkgo Bioworks (NYSE: DNA) insider files to sell 2,200 shares - Stock Titan
Recent Uptick Might Appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Institutional Owners After Losing 13% Over the Past Year - 富途牛牛
Ginkgo Bioworks Partners With Deep Origin-Led Team on ARPA-H to Develop Drug Safety Platform - marketscreener.com
Ginkgo Bioworks Partners on Deep Origin-Led Team to Develop New Tools for Pred Predictive Drug Safety - marketscreener.com
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety - Finviz
Ginkgo Bioworks partners with Deep Origin on ARPA-H drug safety project - Investing.com UK
Ginkgo Bioworks (NYSE: DNA) to aid ARPA-H CATALYST drug safety modeling platform - Stock Titan
Ginkgo Bioworks (NYSE:DNA) Shares Gap UpWhat's Next? - MarketBeat
Ginkgo Bioworks to Hold Special Meeting of Shareholders - GuruFocus
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform - Investing.com
Ginkgo Bioworks secures $47M contract from PNNL for phenotyping platform By Investing.com - Investing.com South Africa
Ginkgo Bioworks Awarded 4-Year Energy Department Contract Valued at Up to $47 Million - marketscreener.com
Ginkgo Bioworks stock rises on $47M DOE contract award By Investing.com - Investing.com South Africa
Ginkgo Bioworks stock rises on $47M DOE contract award - Investing.com India
Ginkgo Bioworks Holdings Inc selected by PNNL to deliver a modular, high-throughput phenotyping platform for DOE's M2PC - marketscreener.com
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High-Throughput Phenotyping Platform for DOE's M2PC - Finviz
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC - marketscreener.com
Will Ginkgo Bioworks Holdings Inc. Class stock announce a stock splitCEO Change & AI Based Buy and Sell Signals - Newser
Is Ginkgo Bioworks Holdings Inc. stock a buy before product launchesMarket Rally & Consistent Growth Equity Picks - Newser
Ginkgo Bioworks Holdings, Inc. $DNA Holdings Boosted by Geode Capital Management LLC - MarketBeat
Ginkgo Bioworks Collaborates With Strm.Bio, Partners on ARPA-H Contract for Cell Engineering, Gene Therapy - marketscreener.com
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy - Finviz
Ginkgo Bioworks (NYSE: DNA) partner STRM.BIO lands ARPA-H deal worth up to $8.4M - Stock Titan
Ginkgo Bioworks Holdings (DNA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ginkgo Bioworks Holdings, Inc. $DNA Position Lifted by Legal & General Group Plc - MarketBeat
Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions (PR Newswire) - Aktiellt
Retail Trends: Is Ginkgo Bioworks Holdings Inc. stock a contrarian buyJuly 2025 Drop Watch & Risk Managed Investment Signals - BỘ NỘI VỤ
Will Ginkgo Bioworks Holdings Inc. stock recover faster than marketJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - BỘ NỘI VỤ
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors (PR Newswire) - Aktiellt
(DNA) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How Ginkgo Bioworks Holdings Inc. Class stock compares with tech leaders2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - newser.com
How Ginkgo Bioworks Holdings Inc. Class stock benefits from digital adoptionStop Loss & Weekly High Potential Stock Alerts - newser.com
Will Ginkgo Bioworks (DNA) Leverage ARPA-H Partnership to Advance Its Oral Therapeutics Ambitions? - Yahoo Finance
Ginkgo Bioworks: Scaling Science, Not Revenue (NYSE:DNA) - Seeking Alpha
Is Ginkgo Bioworks Holdings Inc. Class stock resilient in recession scenarios - newser.com
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Ginkgo Bioworks Holdings Inc. stock daily chart insightsJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Can Ginkgo Bioworks Holdings Inc. stock beat market expectations this quarter - newser.com
Will Ginkgo Bioworks Holdings Inc. stock gain from lower inflationWeekly Market Summary & Real-Time Price Movement Reports - newser.com
Is it time to cut losses on Ginkgo Bioworks Holdings Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
Ginkgo Bioworks Holdings Inc (DNA) 財務データ
収益
当期純利益
現金流量
EPS
0.18%
0.62%
大文字化:
|
ボリューム (24 時間):